Jazz Pharmaceuticals JAZZ Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedEmployeeBenefitsCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accrued compensation?
- Jazz Pharmaceuticals (JAZZ) reported accrued compensation of $182.2M in Q1 2026.
- How has Jazz Pharmaceuticals's accrued compensation changed year-over-year?
- Jazz Pharmaceuticals's accrued compensation increased by 30.7% year-over-year, from $139.39M to $182.2M.
- What is the long-term trend for Jazz Pharmaceuticals's accrued compensation?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accrued compensation has grown at a 16.0% compound annual growth rate (CAGR), from $102.6M to $215.4M.